Novavax (NVAX) Net Income towards Common Stockholders (2010 - 2026)

Novavax's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$9.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 101.83% year-over-year to -$9.5 million; the TTM figure through Mar 2026 stood at -$87.8 million (down 118.35% YoY), while the FY2025 annual figure was $440.3 million, up 334.83% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$9.5 million, down from $17.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $518.6 million in Q1 2025, with the low at -$510.5 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is -$121.3 million (2024), against an average of -$56.5 million.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 244.49% in 2023, then surged 451.51% in 2025.
• Novavax's Net Income towards Common Stockholders stood at -$182.2 million in 2022, then increased by 2.12% to -$178.4 million in 2023, then soared by 54.58% to -$81.0 million in 2024, then soared by 121.63% to $17.5 million in 2025, then tumbled by 154.15% to -$9.5 million in 2026.
• Business Quant data shows NVAX's Net Income towards Common Stockholders at -$9.5 million in Q1 2026, $17.5 million in Q4 2025, and -$202.4 million in Q3 2025.